Cannabichromene (CBC) is one of the primary phytocannabinoids naturally produced by the Cannabis sativa L. plant. First isolated in 1966, CBC remains less studied than tetrahydrocannabinol (THC) or cannabidiol (CBD), although its chemical structure and pharmacological profile suggest it is just as promising. CBC does not produce psychoactive effects, yet it possesses a broad range of potential biological activity.
In the phytocannabinoid system, CBC plays a unique role. It shares structural similarities with other non-psychoactive cannabinoids, such as CBD and CBN, but interacts with different molecular targets, particularly TRP receptors, rather than the CB1/CB2 cannabinoid receptors. Due to these properties, CBC has the potential to modulate the effects of other cannabis compounds, such as reducing THC’s psychoactivity or enhancing the pain-relieving properties of CBD. This opens up possibilities for creating combined phytotherapeutic formulations with targeted effects.
The growing scientific interest in CBC is linked to its potential in neuroprotection, pain management, anti-inflammatory effects, and possible anti-tumor properties. According to research reviews published in the National Library of Medicine, CBC influences a variety of signaling pathways in the body, including both the endocannabinoid and transient receptor systems. As a result, studying CBC is a promising avenue in modern pharmacology, potentially leading to the development of new therapeutic agents without the risk of psychoactive side effects.
How CBC Forms in the Plant
What Are Phytocannabinoids and the Role of CBGA as the “Mother Molecule”
Phytocannabinoids are natural compounds found in plants of the Cannabis genus, particularly in cannabis. They interact with various receptors in the human and animal body, potentially offering therapeutic effects. Cannabinoids like THC, CBD, and cannabichromene (CBC) are among the most well-known.
All of these cannabinoids are derived from a common “mother” molecule, cannabigerolic acid (CBGA). This is the starting point in the biosynthetic pathway for most cannabinoids. CBGA is the key molecule from which, through a series of chemical reactions, all major cannabinoids, including CBC, are produced. It acts as a foundational compound, allowing the plant to create numerous active compounds.
Biochemical Pathway: CBGA → CBCA → CBC
The process of CBC formation in the plant begins with cannabigerolic acid (CBGA). This molecule is a precursor to many cannabinoids, which is why it’s often referred to as the “mother molecule.” Then, under the influence of a specific enzyme, CBC synthase, CBGA is converted into cannabichromenic acid (CBCA).
When the plant is exposed to certain factors, such as during drying or through heat and ultraviolet (UV) light exposure, CBCA loses its carboxyl group (CO₂), leading to the creation of the active form of cannabichromene, CBC. This is a well-known process called decarboxylation.
Thus, the synthesis pathway of cannabichromene looks like this:
CBGA → CBCA → CBC
The Role of Enzymes in CBC Synthesis
Enzymes, specialized proteins that catalyze chemical reactions, play a crucial role in this process. In the case of cannabichromene, it’s the CBC synthase enzyme that catalyzes the conversion of CBGA to CBCA. Without this enzyme, the plant wouldn’t be able to efficiently produce CBC, and the entire cannabinoid production process would be disrupted.
Other enzymes, like THC synthase or CBD synthase, are responsible for the synthesis of other cannabinoids, while CBC synthase specializes in the production of cannabichromene. This allows each cannabinoid molecule to form along its own pathway, and the balance of different cannabinoids in the plant depends on these enzymes.
Factors That Affect CBC Formation
Several important factors influence the synthesis of cannabichromene in the plant, either speeding up or slowing down the process:
- Light: Ultraviolet (UV) light stimulates the breakdown of cannabinoids. Therefore, plants exposed to UV light may have higher cannabinoid activation levels due to decarboxylation.
- Temperature: Heat is a key factor for cannabinoid activation. When the plant is dried or exposed to heat processing, the decarboxylation process happens more quickly. This is particularly important when preparing cannabis for further use, such as oil extraction or creating medicinal products.
- Enzymes: As mentioned, specific enzymes, especially CBC synthase, determine how cannabigerolic acid is converted into cannabichromene. Genetic factors also play a role in regulating the activity of these enzymes.
- Plant Conditions: Humidity, soil type, and other agricultural conditions can affect the amount of CBGA the plant produces, thus influencing the overall cannabinoid balance in the plant.
How CBC Affects the Body
Impact on TRP Receptors, CB2 Receptors, and the Neuroimmune System
TRP Receptors (Vanilloid Receptors): One of the primary mechanisms through which cannabichromene (CBC) exerts its effects is its ability to interact with TRP receptors (receptors sensitive to temperature and pain). Specifically, research shows that CBC interacts with TRPV1 receptors, which are responsible for transmitting pain and temperature sensitivity. By influencing these receptors, CBC can reduce pain associated with inflammation, making it potentially effective for treating chronic pain and pain linked to arthritis and other inflammatory conditions.
CBC also interacts with TRPA1 receptors, which are involved in detecting chemical and physical stimuli, such as pain or cold. Reducing the activity of these receptors helps decrease pain sensitivity while maintaining normal skin sensitivity, which can be beneficial in treating neuropathic pain and other stress-related reactions.
CB2 Receptors (Immune Receptors): In addition, cannabichromene has the ability to interact with CB2 receptors, found in immune system cells, particularly in tissues experiencing inflammation. CB2 receptors are the main receptors that regulate inflammatory processes in the body, making them crucial for combating chronic inflammatory diseases like arthritis or bowel diseases, including Crohn’s disease. By interacting with CB2 receptors, CBC can help reduce inflammation and has the potential to be useful in treating autoimmune diseases and other conditions where the immune system attacks the body’s own tissues.
Neuroimmune System: Cannabichromene also affects the neuroimmune system. Some studies suggest that CBC may influence the activity of macrophages-immune system cells responsible for clearing harmful particles, immune cells, and pathogens from the body. This could help reduce inflammatory responses in tissues, particularly within the central nervous system and peripheral nerve pathways, which is important for treating diseases like neurodegenerative disorders that are accompanied by chronic inflammation.
Research Data from Animal Studies and Laboratories
Most CBC studies are conducted on animals, as this allows for more accurate and controlled data collection. For example, studies on mice have shown that cannabichromene can reduce inflammation and alleviate pain in conditions resembling chronic pain associated with arthritis. Additionally, CBC has shown significant potential in fighting the development of cancer cells. In one laboratory model, it was demonstrated that cannabichromene could slow the growth of cancer cells, including those in breast tumors and other tissues.
However, while these studies are promising, further clinical trials are needed to fully understand the effectiveness of cannabichromene in human treatments.
Advantages of CBC Over Other Cannabinoids
Non-Psychoactivity: One of the main advantages of cannabichromene is that it does not produce psychoactive effects, unlike THC, which alters consciousness and causes euphoria. This makes CBC safe for use in various medical applications where avoiding psychoactive side effects is important, such as in the treatment of chronic pain or inflammation.
Anti-Inflammatory and Analgesic Activity: Despite its lack of psychoactive effects, cannabichromene possesses potent anti-inflammatory and pain-relieving properties, making it useful for treating a wide range of conditions. Laboratory-studied effects, such as reduced pain associated with arthritis and inflammation, suggest its potential for clinical use.
Combinations with Other Cannabinoids: Cannabichromene may be particularly useful in combination with other cannabinoids like CBD or THC, as it helps enhance their therapeutic effects without causing psychoactive side effects. This opens up new possibilities for developing formulations that combine the positive effects of different cannabinoids while maintaining safety for users.
Potential Medical Applications of Cannabichromene (CBC)
Anti-Inflammatory Effects
Cannabichromene (CBC) exhibits significant anti-inflammatory activity, making it particularly promising in the treatment of diseases associated with chronic inflammation. Inflammation is the root cause of many conditions, such as arthritis, asthma, Crohn’s disease, and other autoimmune disorders. A key mechanism of CBC’s action is its effect on CB2 receptors, part of the endocannabinoid system, which regulate the immune response. CBC can reduce the activity of certain molecules, such as cytokines, that are involved in the development of inflammatory processes.
Studies have shown that CBC can reduce inflammation in various tissues, enabling effective management of pain and inflammation. Specifically, there is evidence suggesting that CBC reduces inflammation in nerve tissues, making it potentially beneficial for treating inflammatory diseases of the nervous system. This opens new possibilities for treating conditions such as joint pain or osteoarthritis, where inflammation is a primary factor in disease development.
Pain-Relieving Effects
Cannabichromene also possesses analgesic properties, making it potentially effective for pain relief, especially in cases of chronic pain that are difficult to manage with conventional methods. Research shows that CBC may influence TRP receptors, particularly TRPV1 receptors, which play a key role in transmitting pain signals. These receptors are critical targets for pain-relief medications.
One of the advantages of CBC is that it is non-psychoactive, unlike THC, which can alter mental states and cause euphoria. This makes CBC a viable option for pain management without the risk of side effects related to mental state changes. This makes CBC particularly attractive for long-term pain relief in conditions such as chronic pain, neurological disorders, or post-surgical recovery.
Moreover, CBC may be useful in reducing pain associated with inflammation, as seen in conditions like arthritis and migraines. Animal studies have demonstrated CBC’s ability to reduce pain in chronic diseases, raising hope for its effectiveness in human treatment.
Potential Antidepressant Effects
Research also suggests that CBC may have potential in treating depression and anxiety disorders. CBC can interact with various receptors in the brain, particularly serotonin receptors, which play a crucial role in mood regulation and emotional states. A deficiency in serotonin is one of the primary causes of depression, and CBC may help restore normal function to serotonin systems in the body.
Preliminary results from laboratory studies show that CBC can improve mood and reduce anxiety, making it beneficial for individuals suffering from depressive or anxiety disorders. This is especially important considering that traditional antidepressants often come with significant side effects, such as drowsiness, nausea, or even dependency.
Given this, CBC could represent a promising new therapy for depression and anxiety disorders without the severe side effects commonly associated with many current antidepressants. However, further clinical studies are needed to definitively confirm this hypothesis.
Role in Combating Cancer and Multiple Sclerosis
There is early data suggesting that cannabichromene may possess anti-cancer properties, although most research is still in the preliminary stages. CBC has shown the ability to reduce the growth of certain types of cancer cells, particularly breast cancer, and may have a positive effect on other forms of cancer, such as skin and prostate cancer. Importantly, CBC does not exhibit toxicity to healthy cells, making it safe for long-term use. CBC may also act synergistically with other cannabinoids like CBD, which already shows considerable promise in cancer treatment.
Preliminary laboratory studies on cell cultures have shown that CBC can reduce the metastatic ability of cancer cells. This opens up possibilities for new combination therapies in cancer treatment, where CBC could become an essential component of therapy.
As for multiple sclerosis (MS), cannabichromene also shows promising results. Studies have shown that CBC can reduce inflammation in the central nervous system, which is critical for MS patients. It is believed that CBC may reduce nerve cell damage and improve the function of myelin, which is vital for maintaining neuroprotection in this disease.
What Scientists Say: An Overview of CBC Research
Current Research on CBC: What Is Known
Research interest in cannabichromene (CBC) has significantly increased over the last decade. This is because CBC is one of the main non-intoxicating phytocannabinoids, exhibiting biological activity similar to CBD but possessing its own unique mechanisms of action. It has been primarily studied in experimental models—both in vitro and in vivo—focusing on its anti-inflammatory, neuromodulatory, analgesic, and cytotoxic effects.
Anti-Inflammatory Properties
Several in vivo studies confirm that CBC effectively reduces inflammation. In carrageenan-induced edema models, CBC shows a dose-dependent reduction in the volume of affected tissue. The mechanism is not associated with CB1 receptors but is likely mediated through TRP receptors (TRPA1, TRPV1) and inhibition of pro-inflammatory cytokines. For instance, CBC suppressed the production of TNF-α and NO in activated BV2 microglial cells, indicating its potential as an anti-inflammatory agent in neuroinflammation (Shinjyo et al., 2014, Neurochem Int).
Analgesic Activity
CBC influences pain sensitivity through interactions with TRPA1 and CB2 receptors. In experimental models of neuropathic pain, CBC reduces mechanical allodynia and thermal hyperalgesia. When combined with other cannabinoids like THC or CBD, the analgesic effect is enhanced, suggesting a potential synergistic mechanism—often referred to as the entourage effect.
Neurogenesis and Support for the Nervous System
CBC stimulates the proliferation of neural stem cells in the subventricular zone of the brain, which is involved in the formation of new neurons. This has been observed in vitro in neural cell cultures. In a study by Valdeolivas et al. (2012), CBC promoted cell survival and increased their proliferative activity, especially in combination with CBD. This effect may be particularly important for neurodegenerative diseases—such as Alzheimer’s, Parkinson’s disease—and post-stroke recovery.
Antidepressant Potential
CBC demonstrates antidepressant-like properties in animal models (for example, the forced swim test). The mechanism of this effect may be linked to modulation of the endocannabinoid system and serotonin levels. Research by El-Alfy et al. (2010) showed that CBC reduced depressive-like behavior in mice, similar to CBD, without psychoactive effects.
Antitumor Activity
In laboratory conditions, CBC exhibited cytotoxic activity on oncogenic cells, particularly breast cancer cells. CBC inhibited their proliferation and induced apoptosis without damaging healthy cells. In a study by Ligresti et al. (2006, Journal of Natural Products), CBC, along with other non-intoxicating cannabinoids, effectively reduced the viability of cancer cells at concentrations lower than CBD.
What Is Not Yet Fully Studied or Only Partially Understood
There is a lack of large-scale clinical studies on humans. Most available data comes from studies on mice or cell cultures.
- Pharmacokinetics: The pharmacokinetics of CBC in humans are virtually unstudied. Data on its metabolism, bioavailability, and duration of action are limited.
- Long-term Safety: The safety of CBC for long-term use is not confirmed. There is no reliable information regarding potential toxicities or side effects in humans.
- Effectiveness Compared to CBD or CBG: Direct comparisons in standardized conditions are needed to evaluate CBC’s efficacy in comparison to CBD or CBG.
Conclusions
Cannabichromene (CBC) is one of the primary non-intoxicating phytocannabinoids that is gaining increasing scientific attention. Unlike THC, CBC does not produce psychoactive effects; however, it demonstrates a range of biologically active properties, including modulation of pain, inflammation, neurogenesis, and possibly tumor growth. In plants, it is synthesized from cannabigerolic acid (CBGA), the “mother molecule” for most phytocannabinoids.
Among other cannabinoids, CBC stands out due to its unique action profile: it activates TRP receptors, CB2 receptors (but not CB1), interacts with the immune system, nervous tissue, and possibly the gut microbiome. This makes it promising for research in the context of neurological disorders, chronic pain, inflammatory conditions, anxiety, and potentially depression and cancer.
Current scientific data—mostly from in vitro and in vivo models—indicates CBC’s multifaceted effects, but there is still a lack of clinical studies in humans. In particular, its pharmacokinetics, metabolism, effectiveness in real-life pathologies, interactions with other cannabinoids (the so-called “entourage effect”), and potential risks of long-term use need further clarification.
The research prospects for CBC are vast. Since CBC can influence inflammatory cascades without any psychoactive effects, it has the potential to become an alternative or complement to traditional pharmacotherapy for chronic conditions, particularly without the risk of dependency. However, the scientific community advises caution in drawing conclusions until results from randomized clinical trials are obtained.
Important note: This publication is for informational and scientific purposes only and should not be considered medical advice. CBC should not be used as a treatment without consulting medical or scientific experts, as dosage, form, purity, and combinations with other substances can significantly affect its efficacy.
References
- Shinjyo, N., & Di Marzo, V. (2014).
The effect of phytocannabinoids on inflammatory cytokines released from microglial cells.
Neurochemistry International, 64, 1–8.
https://pubmed.ncbi.nlm.nih.gov/24184696/ - Ligresti, A., et al. (2006).
Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma.
Journal of Pharmacology and Experimental Therapeutics, 318(3), 1375–1387.
https://pubmed.ncbi.nlm.nih.gov/16818650/ - El-Alfy, A. T., et al. (2010).
Antidepressant-like effect of Δ9-tetrahydrocannabinol and other cannabinoids in animal models of depression.
Pharmacology Biochemistry and Behavior, 95(4), 434–442.
https://pubmed.ncbi.nlm.nih.gov/20332000/ - Valdeolivas, S., et al. (2012).
Cannabinoid CB2 receptor agonist ameliorates neurodegeneration in experimental models of Huntington’s disease.
Journal of Neuroscience Research, 90(5), 1099–1110.
https://pubmed.ncbi.nlm.nih.gov/23181098/ - De Petrocellis, L., et al. (2011).
Effects of cannabinoids on TRP channels and endocannabinoid metabolic enzymes.
British Journal of Pharmacology, 163(7), 1479–1494.
https://pubmed.ncbi.nlm.nih.gov/21323910/ - Andre, C. M., Hausman, J. F., & Guerriero, G. (2016).
Cannabinoids in medical cannabis: From plant to patient.
Trends in Plant Science, 21(5), 370–385.
https://doi.org/10.1016/j.tplants.2015.12.004 - PubChem Database – CBC (Cannabichromene)
Наукова хімічна база даних від NCBI
https://pubchem.ncbi.nlm.nih.gov/compound/Cannabichromene - Hanuš, L. O., Meyer, S. M., Muñoz, E., Taglialatela-Scafati, O., & Appendino, G. (2016).
Phyto-cannabinoids: A unified critical inventory.
Natural Product Reports, 33(12), 1357–1392.
https://pubs.rsc.org/en/content/articlelanding/2016/np/c6np00074f
